gull embryos exposed in ovo to DDT and other pesticides (4) . Similarly, the decreased reproductive success of alligators and turtles in Lake Apopka, Florida, was linked to a spill of kelthane, a pesticide formulation containing DDE (5) . Other evidence that certain chemicals acted as endocrine disruptors was revealed when various occupational exposures in humans were reported. In 1949, aviation crop dusters handling DDT were found to have reduced sperm counts (6) . While a single causal agent can be identified in cases in which humans have had occupational exposures, wildlife showing signs of reproductive damage are usually exposed to a combination of endocrine disruptors. Additionally, some of these chemicals may traverse the human placenta and have the potential to adversely affect the developing fetus (7) . Although some of these effects may be obvious upon birth, others may not manifest themselves until sexual maturity has been reached. For example, boys exposed in utero to PCBs appeared normal during childhood, but at puberty their penises were significantly smaller than those of nonexposed controls (7) .
It has been hypothesized that environmental estrogens may play a role in the declining quantity and quality of human semen during the last 50 years, as well as in the increased incidence of testicular cancer and cryptorchidism in males and breast cancer incidence in both females and males in the industrialized world (8) (9) (10) . Regarding breast cancer, the main risk factor for its development is exposure to estrogens throughout an entire lifetime (11) . Moreover, increased plasma levels of "bioavailable" ovarian estrogens (not bound to sex hormone-binding globulin [SHBG] ) in postmenopausal women correlate positively with breast cancer (12) .
Among the estrogenic xenobiotics, PCBs and DDT were considered suitable markers of exposure for breast cancer because they were released massively into the environment beginning approximately 50 years ago and they are persistent; their presence in serum may represent cumulative exposure during a lifetime. Three recent studies showed a correlation between the occurrence of breast cancer and levels of xenoestrogens. Wolff et al. (13) found that serum DDE levels correlated with breast cancer incidence in a study of 58 breast cancer patients and 171 controls that were well matched for risk factors and age.
Another study documented that estrogenreceptor positive breast cancer correlated with higher concentrations of DDE in their tissues (14) . Krieger et al. (15) studied 150 women with breast cancer and 150 controls; each set consisted of 50 African-American, 50 Caucasian, and 50 Asian-American women. When the data from all ethnic groups were pooled, no significant correlation was observed between plasma levels of DDE and breast cancer (15) . However, when the cases and matching controls were evaluated separately, according to their ethnic group, high serum DDE levels were correlated with breast cancer incidence in Caucasian and African-American women but there was no significant correlation in Asian-American women. Evidence of a link between exposure to PCBs and breast cancer incidence is equivocal (16) . However, these studies correlated exposure to total PCBs, rather than to the levels ofspecific congeners.
Epidemiological studies should be conducted involving larger sample sizes to clarify the relevance of these findings. It would be impractical to test only for the presence of DDT metabolites and PCBs since not all the PCB congeners are estrogenic, and many other environmental estrogens may also play a role. The newly identified estrogens may be less persistent than PCBs and DDT metabolites; however, they are widely used and exposure may occur steadily due to their presence in foods (3) . Measuring the levels of each of the xenoestrogens in blood is a better approximation of real exposure at the target organ level than inferring cumulative exposure from estimation of mass balance of dietary levels. However, cumulative estrogenicity of mixtures cannot be directly deduced from individual xenoestrogen plasma levels. Two approaches may be used to assess total load: a) the development of methods to study mixtures of these xenoestrogens in order to quantify their cumulative effects and to begin to understand their interactions (i.e., additivity, synergy, antagonism, or independent action), so that plasma concentrations may be translated into units of activity such as "estradiol equivalents," and b) the development of methods to separate xenoestrogens from ovarian estrogens in blood and directly measure the estrogenic activity of the xenoestrogen extract using a bioassay. This In our experimental design, MCF-7 cell yields were measured 6 days after to; however, significant differences between control and estrogen-treated cultures are already apparent after 4 days (21) .
The estrogenic activity of xenobiotics was assessed by determining relative proliferative potency (RPP); this is 10Ox the ratio between the minimal concentration of estradiol needed for maximal cell yield at 6 days and the minimal dose of the test compound needed to achieve a similar effect, and by measuring relative proliferative effect (RPE); this is 10Ox the ratio between the highest cell yield obtained with the chemical and with estradiol. The RPE indicates whether or not the compound being tested induces a proliferative response quantitatively similar to the one obtained with E2, that is, a full agonist (RPE = 100), or a proliferative yield significantly lower than the one obtained with E2, that is, a partial agonist. When combined with estradiol, antagonists significantly lower the proliferative yield obtained with estradiol alone.
Antagonistic Effect
The E-SCREEN bioassay was also used to evaluate possible antagonistic activity of xenobiotics used in the cumulative effect experiments. Bisphenol-A (BPA) and p,p'-DDE were tested at a range of concentrations with and without the addition of 100 pM estradiol. The proliferative yield was compared to the steroid-free control. The differences between the estradiol-treated groups were assessed by a posteriori Shaffe's test (22 Burse et al. (23) , with modifications (1). To develop the extraction procedure, CD-serum was used for spiking and as a "blank" preparation. The extracts from the "blank" preparations are devoid of absorbance at 280 nm, and therefore do not interfere with the quantification of added xenoestrogens. In addition, CD-treated serum is lacking in estrogenic activity; this also holds for quantitation of the spiked estrogen by means of the E-SCREEN bioassay. To assess the recovery of xenoestrogens from serum, 4-ml aliquots of CD-treated serum were spiked with a known amount of standard xenoestrogen and allowed to equilibrate for 2 hr at room temperature.
Sample Extraction. Methanol (2 ml) was added to each of two 4-ml aliquots of serum, mixed by vortexing, and then 5 ml of hexane: ethyl ether (1: 1, by vol) was added to extract the mixture. The mixture was first agitated on a rotary mixer for 15 min and then centrifuged at 2000xg for 5 min. The organic phase was collected, and the aqueous phase was extracted twice more. The organic phases were pooled and subsequently concentrated to 1 ml by evaporation under a nitrogen stream.
Acid Cleanup of the Organic Phase Prior to HPLC. Concentrated sulfuric acid (0.5 ml) was added to the concentrated 1-ml sample of organic phase. The sample was briefly vortex-mixed and then centrifuged for was pipetted into 9.9 ml of the CD-treated culture medium (5% CD-treated human serum). This sample is designated "undiluted preparation," and from it, the serial 2-fold dilutions were made; 1:1, 1:4, 1:8, 1:16, and 1:32. After equilibration at room temperature for 20 min, the preparation was rendered sterile by filtration through a 0.22 pm (pore size) membrane. The dilutions were assayed by the E-SCREEN test. A "blank" was prepared from CD-treated human serum by following the fractionation protocol that was described for the preparations spiked with known amounts of xenoestrogens.
Quantafication. To obtain calibration curves, chemicals to be analyzed were injected at five to seven different doses, ranging from 0 to 500 nmol. The correlation coefficient for each curve was 0.99.
Results
Identification ofXenoestrogens
by the E-SCREEN Assay
The three isomers of phenylphenol, DDT (technical grade), and DDT metabolites were tested for estrogenicity ( o,p'-DDT, o,p'-DDD, and p,p'-DDT were full agonists; meanwhile p,p'-DDE, and p,p'-DDD were partial agonists. DDT (technical grade) was a full agonist; this was expected since it consists of 20% of o,p'-DDT and 80% ofp,p'-DDT.
In testing for antagonistic effects, BPA (a full agonist) did not alter the proliferative effect of estradiol (Figure 1 ). BBP and 2,2',3,3',6,6'-HCB were also tested; they had no antagonistic effect (data not shown). The partial agonist p,p'-DDE showed statistically significant, partial antagonistic effects on MCF-7 cell proliferation ( Figure 1 ).
Development ofa Method to Reveal Cumulative Effects ofXenoestrogens
The first step toward this end was to evaluate the sensitivity of the E-SCREEN test by means of a detailed estradiol dose-response curve (Figure 2) . At any concentration below 1 pM (1 fmol in 1 ml culture medium), the mean cell number did not differ significantly from the steroid-free estradiol ( Figure 4A ) and o,p'-DDT ( Figure 4B ) were (Figure 2 ) using normalized mean cell number of four experiments ± SD. Calculated EEqs were determined by adding the EEqs of the mixture components. Measured EEqs were interpolated from E2 dose-response curve (Figure 2 ) using the normalized mean cell number of four experiments ± SD. The calculated and measured EEqs for each mixture were significantly different using chi square analysis (p< 0.05). "Negative control: cell yield in 50 ml/liter CD-treated serum alone. in the presence of 5% CD-treated serum, indicating the absence of estrogenic activity ( Figure 5A ). Microscopic observation did not reveal any toxic effects. Additionally, a full estrogenic response was obtained when 100 pM estradiol was added to this preparation ( Figure SA) . The spiked serum extract was also tested at various dilutions.
The recovery of spiked o,p'-DDT was 84% (83 and 85%). Thus, the most concentrated dilution ("undiluted") was approximately 12 pM. As shown in Figure SB , the dilution curve of the spiked preparation is in agreement with the dose-response curve to o,p'-DDT added directly to 5%
CD-treated human serum supplemented medium in Figure 4B . Lack of toxic activity in this extract is demonstrated by maximal estrogenic activity when each dilution of the spiked extract was tested in the presence of 100 pM estradiol ( Figure 5B ).
Discussion
In addition to being exposed to their own steroidal estrogens, humans and wildlife are also exposed to synthetic xenoestrogens (pesticides, plasticizers, antioxidants, etc.) and natural ones, such as phytoestrogens. There has been controversy regarding which DDT metabolites are estrogenic, and also their relevance to breast cancer incidence (28) . The E-SCREEN assay revealed that all the assayed metabolites are estrogenic. Additionally, full agonists are devoid of antagonistic effects ( Figure 1) ; partial agonists are also partial antagonists ( Figure  1 ). The antagonistic activity of these compounds, although statistically significant, is biologically marginal (Figure 1 ). Figure 1 ), while it is claimed by some to be devoid of estrogenicity in the rat model (28) . In addition to cell proliferation, other markers of estrogenic activity, such as the PgR assay and pS2 assay in MCF-7 cells, are adequate for assessing estrogenicity in humans. Cell proliferation assays are more sensitive than those that induce gene products (1, (29) (30) (31) Figure 3) . The analysis of the interaction of E-SCREEN xenoestrogens in the mixtures of three and ididate for four chemicals indicates that the effect of indard of the mixture is 2-to 3-fold higher than the ells at the expected effect, assuming simple additivity. The extraction/clean-up methodology of pesticides from human serum, described by Burse et al. (23) (1) . When the Sep Pak step was eliminated, the toxic effect disappeared ( Figure 5 ). This method resulted in 83 to 85% recovery of the spiked op'-DDT. Moreover, the biological activity accurately paralleled the doseresponse curve to this chemical. Therefore, it is now feasible to use this method to measure, in serum, the cumulative effect of the xenoestrogens tested thus far, since they were separated from ovarian estrogens.
We propose to measure the combined effect of the compounds eluted during the first 10 min of our HPLC separation as a marker of exposure to xenoestrogens. Estrogenic pesticides, PCBs, hydroxylated PCBs, phenolic antioxidants, and plasticizers elute from the HPLC column during the first 10 min, whereas ovarian estrogens, phytoestrogens, diethylstilbestrol, and mycoestrogens are retained for more than 12 min (1) . Populations that will be investigated are not expected to have been exposed to DES or mycoestrogens. Further optimization of the HPLC separation protocols may allow the separation of phytoestrogens from ovarian estrogens.
The data and analysis presented here represents an attempt to cope with intensifying demands by the public and regulatory agencies to rigorously evaluate the role of xenoestrogens in the increased incidence of male genital tract anomalies, testicular cancer, and breast cancer in human populations. In this article, we use novel extraction protocols and HPLC to measure the cumulative exposure to xenoestrogens. The full development of this concept into a reliable method to measure exposure in human populations will require further validation. Additional techniques, aimed at identifying all of the individual estrogenic xenobiotics present in serum samples of people suspected of being exposed, will help in correlating the relative contribution of each xenoestrogen with the observed health effect in exposed individuals.
